Alan Frazier is the founder and managing partner of Frazier Healthcare Ventures. Since 1991, the firm has raised seven venture capital funds representing $1.8 billion in committed capital and has invested in over 100 emerging life science companies. Mr. Frazier assists with evaluating biopharmaceutical, medical device and growth equity investments. He has been integrally involved in growing several successful early-stage life science companies into national prominence such as Immunex, Affymax and Affymetrix and has secured premiere deal flow through early-stage investments such as Tularik and CV Therapeutic on behalf of Frazier Healthcare.
Currently Mr. Frazier serves on the boards of Alexza Pharmaceuticals (NASDAQ: ALXA), Ascension Orthopedics, Cadence Pharmaceuticals (NASDAQ: CADX), Calixa Therapeutics, Nuon Pharmaceuticals, Portola Pharmaceuticals, and Trilogy Health.
In the past he has served on the boards of Array BioPharma (NASDAQ: ARRY), Calistoga Pharmaceuticals, GenQuest, InControl (NASDAQ: INCL), Informed Medical Communications, NeoPath (NASDAQ: NPTH), OnHealth (NASDAQ: ONHN), PatientKeeper, Rigel (NASDAQ: RIGL), Stromedix and Tularik.
Prior to forming Frazier Healthcare Ventures, Mr. Frazier was the executive vice president and chief financial officer of Immunex Corporation. Later, he served as the senior financial advisor and chief financial officer of Affymax and worked on the spinout of Affymetrix. Prior to Immunex, Mr. Frazier was head of the Emerging Business Practice and co-head of the Technology Practice for the Seattle office of Arthur Young Company (now, Ernst & Young). Mr. Frazier holds a B.A. in Economics from the University of Washington.
Mr. Frazier also serves on the Boards of the Washington Biotechnology and Biomedical Association and the Western Washington University Foundation. Additionally, he is a member of the University of Washington Medicine Industry Advisory Committee and the Advisory Council for the J. David Gladstone Institute, which is associated with the University of California San Francisco.